Full Text View
Tabular View
No Study Results Posted
Related Studies
Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation (CTX)
This study is ongoing, but not recruiting participants.
Study NCT00297830   Information provided by Columbia University

First Received on February 27, 2006.   Last Updated on February 11, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Heart Transplantation
Liver Transplantation
Bone Resorption
More general conditions related to this trial
Bone Diseases
Musculoskeletal Diseases
Interventions listed in this trial
zoledronic acid
alendronate
Additional drug interventions recognized in this trial
Diphosphonates
More general drug interventions related to this trial
Bone Density Conservation Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
Columbia University
Novartis Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services